| |
Hazard ratio
|
95% confidence interval
|
p-value
|
|---|
|
Univariate analysis
|
|
Age
|
0.995
|
0.884–1.12
|
0.929
|
|
ECOG Performance status = 2
|
0.994
|
0.453–2.18
|
0.987
|
|
Brinkman Index
|
0.999
|
0.998–1.00
|
0.104
|
|
Emphysema
|
0.649
|
0.241–1.74
|
0.391
|
|
Diabetes mellitus
|
0.990
|
0.448–2.189
|
0.980
|
|
Squamous cell carcinoma
|
1.15
|
0.420–3.12
|
0.792
|
|
Major diameter of the primary site
|
1.02
|
0.997–1.03
|
0.102
|
|
Brain metastasis
|
2.82
|
0.986–8.04
|
0.0533
|
|
Bone metastasis
|
3.07
|
1.24–7.57
|
0.0150
|
|
Liver metastasis
|
1.29
|
0.294–5.65
|
0.736
|
|
Adrenal gland metastasis
|
4.77
|
1.21–18.8
|
0.0253
|
|
Carboplatin-based doublet therapy
|
1.12
|
0.513–2.46
|
0.773
|
|
Number of treatment cycles
|
0.665
|
0.483–0.915
|
0.0122
|
|
Lymphocyte count
|
1.00
|
0.999–1.00
|
0.321
|
|
Hemoglobin
|
0.789
|
0.621–1.00
|
0.0511
|
|
Albumin
|
0.180
|
0.0694–0.465
|
0.000408
|
|
Lactate dehydrogenase
|
1.00
|
0.998–1.00
|
0.455
|
|
Calcium
|
1.15
|
0.764–1.72
|
0.51
|
|
C-reactive protein
|
1.08
|
0.961–1.21
|
0.196
|
|
Multivariate analysis
|
|
Bone metastasis
|
1.98
|
0.666–5.90
|
0.2190
|
|
Adrenal gland metastasis
|
2.19
|
0.470–10.17
|
0.3180
|
|
Number of treatment cycles
|
0.744
|
0.518–1.07
|
0.110
|
|
Albumin
|
0.18
|
0.0638–0.508
|
0.00121
|
- In the univariate analysis, serum albumin level, number of cycles, the existence of bone metastasis, and the existence of adrenal gland metastasis, all with p-values <0.05, were selected as candidate factors. A multivariate analysis identified serum albumin level as an independent factor associated with survival
- Abbreviations: ECOG Eastern Cooperative Oncology Group
